Epigenetic and genetic investigation of SOCS-1 gene in patients with multiple myeloma
- Author:
Fatıma Ceren TUNCEL
1
;
Istemi SERIN
;
Sacide PEHLIVAN
;
Yasemin OYACI
;
Mustafa PEHLIVAN
Author Information
- Publication Type:Original Article
- From:Blood Research 2022;57(4):250-255
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:The suppressor of cytokine signaling-1 (SOCS-1) functions to induce an appropriate immune response and is an essential physiological regulator of interferon signaling. DNA methylation involves adding a methyl group to the carbon 5 position of cytosine. Besides comparing SOCS-1 gene methylation status between patients with multiple myeloma (MM) and healthy controls, this study also aimed to demonstrate the effect of SOCS-1 gene distribution and the effect of methylation of SOCS-1 on progression-free survival (PFS) and overall survival (OS).
Methods:This study included 120 patients diagnosed with MM between January 2018 and 2020 and 80 healthy individuals. The distribution of the SOCS-1 genotypes was statistically compared between MM patients and healthy controls. Additionally, the statistically significant effects of these genotypes on survival were examined.
Results:The CA/CA genotype of SOCS-1 was significantly higher in healthy controls (P =0.001), while the Del/Del genotype was significantly higher in patients with MM (P =0.034). The percent methylated reference (PMR) value of the SOCS-1 gene was significantly higher in the healthy controls (median, 43.48; range, 2.76‒247.75; P =0.001). Patients with a PMR value of ≥43.48 were 3.125 times more likely to develop progression than those with a PMR value of ＜43.48.
Conclusion:The effects of SOCS-1 polymorphisms on the pathogenesis of MM and SOCS-1 methylation will further shed light on the pathophysiology of MM.
